Tandem Diabetes Care, Inc. TNDM reported a second-quarter 2026 loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents. The figure improved from the year-ago loss of 78 cents.
Worldwide revenues of $254.6 million rose 5.8% year over year and missed the consensus mark by 0.1%. Worldwide pump shipments exceeded 33,000, rising more than 10% year over year, while gross margin reached 57%.
Following the earnings announcement, TNDM shares gained 19.1% last Friday.
TNDM's U.S. Sales Rise on Supplies Growth
U.S. revenues increased 5% year over year to $179.29 million. Pump revenues declined 3% to $83.00 million, while supplies and other revenues climbed 14% to $96.29 million. U.S. pump shipments exceeded 22,000 compared with approximately 21,000 a year ago.
Tandem's pay-as-you-go, or PAYGO, pharmacy model continued to gain traction. Pharmacy sales represented 10% of total U.S. sales in the quarter. Management said the initial revenue headwind from pumps sold through the pharmacy channel was approximately $8 million because those shipments carry no upfront pump reimbursement.
Tandem Diabetes Sees International Shipment Growth
International revenues rose 7% year over year to $75.27 million and increased 6% at constant currency. Pump sales advanced 20% to $31.65 million, while supplies and other sales slipped 1% to $43.62 million. International pump shipments totaled approximately 11,000, up from roughly 9,000.
Direct-channel sales accounted for about 13% of international revenues, more than double the year-ago level. Results included roughly $3 million of headwinds tied to distributor inventory buybacks and de-stocking ahead of direct-market transitions. Infusion-set supply constraints also limited distributor order fulfillment late in the quarter.
TNDM's Gross Margin Shows Strong Expansion
Gross profit increased to $144.78 million from $125.86 million a year earlier. Gross margin expanded 460 basis points year over year to 57%, reflecting favorable pricing from channel initiatives and product cost improvements as Tandem Mobi volumes scaled.
Operating expenses fell to $158.57 million from $177.67 million. Selling, general and administrative expenses rose to $111.64 million from $109.60 million, while research and development expenses declined to $46.93 million from $48.12 million. The operating loss narrowed to $13.79 million from $51.81 million.
TNDM Maintains 2026 Sales and Margin Outlook
TNDM reaffirmed its 2026 worldwide sales guidance of $1.065 billion to $1.085 billion. U.S. sales are projected between $730 million and $745 million, while international sales are expected to be in the $335-$340 million range. The Zacks Consensus Estimate for full-year revenues is pegged at $1.07 billion.
For the third quarter, management expects worldwide sales of approximately $265 million, comprising about $180 million in the United States and $85 million internationally.
Tandem Diabetes Maintains a Solid Cash Position
Tandem ended the second quarter with $456.00 million in cash, cash equivalents and short-term investments compared with $570 million at the end of the first quarter.
Cash used in operating activities totaled $34.62 million in the quarter compared with $9.50 million a year earlier. Capital expenditures amounted to $4.05 million, resulting in a negative free cash flow of $38.67 million compared with $15.70 million in the prior-year quarter.
Our Take
Tandem Diabetes incurred a narrower-than-expected quarterly loss but missed on revenues. Its performance benefited from higher pump shipments, favorable pharmacy-channel pricing and product cost improvements. A key milestone in the quarter was that the PAYGO formulary coverage reached approximately 45%, approaching the high end of Tandem's 2026 target range. Expansion of gross margin is highly promising.
On a negative note, the company’s loss looks discouraging.
TNDM’s Zacks Rank and Key Picks
Tandem Diabetes currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Quest Diagnostics DGX and Medpace MEDP.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.
DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.
Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.
MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
